There were no fatal treatment-emergent adverse events (TEAEs) in either patient group, but exposure-adjusted incidence rates ...

T-DXd regimens improved pathologic complete response and safety profiles compared to ddAC-THP in high-risk, HER2-positive early breast cancer. Patient-reported outcomes showed better physical ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...

Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast ...

Previous findings from the phase 3 DESTINY-Breast05 study (NCT04622319) showed that T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) ...

New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...

What Is High School DxD? This crossover between High School DxD and VTuber Legend: How I Went Viral After Forgetting to Turn Off My Stream goes to a whole new level as High School DxD’s first three ...